News Releases and Coverage

Valve-in-valve TAVR proves successful in the long-term (Dr. John Webb, SPH)

An analysis of PARTNER 2 data, published in the June edition of the Journal of the American College of Cardiology, suggests transcatheter aortic valve replacement (TAVR) within failed bioprosthetic surgical aortic valves is a viable long-term solution for high-risk individuals, with patients seeing “excellent” functional and quality of life outcomes three years after the procedure.

Valve-in-valve (VIV) TAVR has already seen some success, first author John G. Webb, MD, of St. Paul’s Hospital in Vancouver, Canada, and co-authors wrote in JACC, and we know patients have seen favorable outcomes at the 30-day and one-year marks. But, Webb and colleagues said, few studies have considered the impact of VIV TAVR beyond one year post-procedure.

Read the full story on Cardiovascular Business.

Give us your comments and story ideas

X